Cargando…
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
Despite widespread use of Pegylated forms of Inteferon in the management of Myeloproliferative Neoplasms (MPN), most clinicians have experience predominantly with peginterferon alfa-2a (Pegasys). Third generation pegylated IFNα, ropeginterferon alfa-2b (ropegIFN; Besremi), was recommended by the Eur...
Autores principales: | Okikiolu, Jumoke, Woodley, Claire, Cadman-Davies, Llywelyn, O'Sullivan, Jennifer, Radia, Deepti, Garcia, Natalia Curto, Harrington, Patrick, Kordasti, Shahram, Asirvatham, Susan, Sriskandarajah, Priya, Saunders, Jamie, Saha, Chandan, Sanchez, Irene, deLavallade, Hugues, McLornan, Donal P, Harrison, Claire N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801096/ https://www.ncbi.nlm.nih.gov/pubmed/36590864 http://dx.doi.org/10.1016/j.lrr.2022.100360 |
Ejemplares similares
-
P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
por: Harrington, P., et al.
Publicado: (2022) -
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
por: Harrington, Patrick, et al.
Publicado: (2022) -
Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
por: Mathur, Abhinav, et al.
Publicado: (2022) -
Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center
por: Khan, Alesia, et al.
Publicado: (2021) -
Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021
por: Saunders, Jamie, et al.
Publicado: (2021)